Veralize - Universal Nucleic Acid Detection Platform
12-15 Molecular Diagnostics, Inc. (12-15MD), East Haven, Connecticut, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Veralize Solution: Simple and elegant, exceeding 'Sprint' sensitivity threshold, patented technology exposes primed with c-DNA graphene-carbon-nanotubes to the target nucleotide, for one-step sensing. Multiple pathogen detection demonstrated. Self-sterilizing SARS-COV-2 noninvasive saliva assay has 20 minutes turnaround at a Point of Contact clinical trials. Solution can serve home use.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: The Care industries are in dire need for rapid and adaptable diagnostic solutions. Veralize is designed to swiftly adapt and address at scale the changing diagnostic needs for detection of pathogens and mutations driving disease processes in humans and animals. Its IT features enable users to notify appropriate recipients without delays and in privacy. Launch of the Point of Care assay for Covid19 will lessen the burden on the healthcare front lines by reducing demands on personnel, protective equipment, and logistics. Next generation will enter POC market with detection of then current selection of prevalent pulmonary and enteric pathogens. The instrument is designed to Healthcare needs and the platform is adaptable to the Food and pharmaceutical industries need for control of gene-specific products and processes (genetic selection, purity, mutation surveillance in for instance fermentation products). With the option for developing remote detection of molecular genetic products, our technology is poised for penetration of these areas. As a long term impact we envision involving the Insurance industry which uses such data for mitigation of business risks in relation to health, farming and related industries.